VBI Vaccines (NASDAQ:VBIV) Downgraded by Zacks Investment Research to “Sell”

VBI Vaccines (NASDAQ:VBIVGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

Separately, Raymond James reduced their target price on shares of VBI Vaccines from $9.00 to $6.00 and set a “strong-buy” rating for the company in a report on Tuesday, March 8th.

Shares of NASDAQ VBIV traded down $0.04 during mid-day trading on Tuesday, reaching $1.30. 17,522 shares of the company traded hands, compared to its average volume of 1,730,745. VBI Vaccines has a fifty-two week low of $1.21 and a fifty-two week high of $4.31. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.00 and a quick ratio of 3.92. The firm has a market cap of $334.49 million, a PE ratio of -4.81 and a beta of 2.01. The stock has a fifty day simple moving average of $1.51 and a 200-day simple moving average of $2.06.

VBI Vaccines (NASDAQ:VBIVGet Rating) last issued its earnings results on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.07). The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.14 million. VBI Vaccines had a negative net margin of 11,054.36% and a negative return on equity of 42.79%. As a group, analysts predict that VBI Vaccines will post -0.31 EPS for the current fiscal year.

Several large investors have recently modified their holdings of VBIV. SG Americas Securities LLC boosted its stake in shares of VBI Vaccines by 509.9% during the 3rd quarter. SG Americas Securities LLC now owns 76,095 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 63,618 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in shares of VBI Vaccines by 64.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 222,474 shares of the biopharmaceutical company’s stock valued at $692,000 after buying an additional 86,980 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of VBI Vaccines by 433.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,448 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,863 shares during the period. Swiss National Bank raised its holdings in shares of VBI Vaccines by 5.2% during the 3rd quarter. Swiss National Bank now owns 393,100 shares of the biopharmaceutical company’s stock valued at $1,223,000 after purchasing an additional 19,600 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new position in shares of VBI Vaccines during the 3rd quarter valued at $34,000. 43.24% of the stock is owned by institutional investors.

VBI Vaccines Company Profile (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Stories

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.